neeed f lu vvacaccine? · 2014. 4. 10. · j7195 j7195 j7195 j7195 j7194 j7194 j3590 te *all codes...

Ne

cine?acVVaclu eed F

ww800To Pro

Ea

ww.MyFluVaccine.com0-843-7477 Order:oduct details pg. 10

arly order discountswill expire soon!

m

A SESIRPRETNEFFFFOMARGORPA

4102LIRPAProduct Catalog

Coagulation Products 6

Immune Globulins 8

Hyperimmune Globulins 9

Albumin | Plasma Protein Fraction 9

Inuenza Vaccines and Antivirals 10

Other Vaccines 11

Surgical Sealants 12

Other Specialty Products 12

C

F A

Coagulation Products*

TE 5 ML 00944 2948 10 J7192

FACTOR VIII (HUMAN–PLASMA DERIVED)

VON WILLEBRAND FACTOR / FACTOR VIII COMPLEX (HUMAN-PLASMA DERIVED)

FACTOR VIII (RECOMBINANT)

ANTI-INHIBITOR (HUMAN-PLASMA DERIVED)

FACTOR VIIa (RECOMBINANT)

EDOCRERUTCAFUNAMREBMUNCDNEZISNOITPIRCSED

J7192TER XBA

00944-2965-10 VIAL 4000 IU AATE 5 ML ADVVA

TE 5 ML J7192

TER XBA00944-2964-10

VIAL 3000 IU AATE 5 ML ADVVATE 5 ML

J7192TER XBA


TE 5 ML J7192

TER XBA00944-2962-10


J7192TER XBA


TE 5 ML J7192

TER XBA00944-2960-10


J7192TER XBA


TE 2 ML J7192

TER XBA00944-2923-02


J7192TER XBA


TE 2 ML J7192

TER XBA00944-2921-02


J7183

TER XBA

67467-0182-02

VIAL 250 IU AATE 2 ML ADVVA

TE J7183

A APHARMTTAPHARMOC67467-0182-01

+VIAL1000 IU WILAATE TE

J7187A APHARMTTAPHARMOC

63833-0617-02 +VIAL500 IU WILAATE

TE P J7187

CSL BEHRING 63833-0616-02

+VIAL2400 IU AATE P HUMTE P

J7187CSL BEHRING

63833-0615-02 +VIAL1200 IU AATE P HUM

TE P J7186


+VIAL600 IU AATE P HUMTE

J7186GRIFOLS

68516-4603-02 +VIAL1500 IU ALPHANAATE

TE J7186

GRIFOLS 68516-4602-01

+VIAL1000 IU ALPHANAATE TE

J7186GRIFOLS

68516-4601-01 +VIAL500 IU ALPHANAATE

TE

J7190

GRIFOLS

76125-0667-50

+VIAL250 IU ALPHANAATE

TE DVI J7190

KEDRION 76125-0500-30

VIAL 1000 IU AATE DVI OKTE DVI

J7190KEDRION

76125-0250-20 VIAL 500 IU AATE DVI OK

TE DVI

J7189

KEDRION

00169-7040-01

VIAL 250 IU AATE DVI OK

T J7189

NOVO NORDISK 00169-7050-01

VIAL 8 MG VEN RNOVOSET

J7189NOVO NORDISK

00169-7020-01 VIAL 5 MG VEN RNOVOSE

T J7189

NOVO NORDISK 00169-7010-01

VIAL 2 MG VEN RNOVOSET

J7198

NOVO NORDISK

64193-0225-02

VIAL 1 MG VEN RNOVOSE

EIBA NF J7198

TER XBA64193-0224-02

t II VIAL w/Baxjec2500 IU EIBA NF

J7198TER XBA

64193-0223-02 t II VIAL w/Baxjec1000 IU

EIBA NF TER XBAt II VIAL w/Baxjec500 IU

tsod

ucr

P K

F

F

K

NNNN

F F F

tion

oagu

laC

W

V

WHHHAAAA

K

A

F

AAAAAAAAAA

TE 00944-2845-10 J7192tinuedonc.alueso vCor Reen fing scrderall (800) 843-7477 or check or C+. eryvider and the paoeen the prwi�ed beterodes should be vll c*A

moc.eniccaVulFyM.www|moc.sesirpretneFFF.www|3334-814)008(xaF|7747-348)008(:REDROOT

J7192TER XBA

00944-2844-10 VIAL 2000 IU OMBINAATE REC

TE J7192

TER XBA00944-2843-10

VIAL 1500 IU OMBINAATE RECTE

J7192TER XBA


TE J7192

TER XBA00944-2841-10

VIAL 500 IU OMBINAATE RECTE

J7192TER XBA


TE FS J7192

ER YBAAY00026-3786-60

VIAL 3000 IU OGENAATE FS KTE FS

J7192ER YBAAY

00026-3785-50 VIAL 2000 IU OGENAATE FS K

TE FS J7192

ER YBAAY00026-3783-30


J7192ER YBAAY

00026-3782-20 VIAL 500 IU OGENAATE FS K

TE FS J7192

ER YBAAY00026-3797-70


J7192ER YBAAY

00026-3796-60 T VIAL w/BIOSE3000 IU OGENAATE FS K

TE FS J7192

ER YBAAY00026-3795-50

T VIAL w/BIOSE2000 IU OGENAATE FS KTE FS

J7192ER YBAAY


TE FS J7192

ER YBAAY00026-3792-20

T VIAL w/BIOSE500 IU OGENAATE FS KTE FS

J7192ER YBAAY


TE FS J7192


VIAL 3000 IU AATE FS HELIXTE FS

J7192CSL BEHRING

00053-8133-02 VIAL 2000 IU AATE FS HELIX

TE FS J7192


VIAL 1000 IU AATE FS HELIXTE FS

J7192CSL BEHRING

00053-8131-02 VIAL 500 IU AATE FS HELIX

TE FS J7192


VIAL 250 IU AATE FS HELIXTE 5 ML TER XBAVIAL 4000 IU AATE 5 ML ADVVA

6

OFUSE 58394-0016-03

continued

FACTOR VIII (MONOCLONAL PURIFIED)

FACTOR VIII (RECOMBINANT) Continued

FACTOR IX (HUMAN–PLASMA DERIVED)

FACTOR IX (MONOCLONAL PURIFIED)

FACTOR IX (RECOMBINANT)

OTHER COAGULATION PRODUCTS

E

TH EWY58394-0025-03

3000 IU KIT NTHA SOLYXOFUSE TH EWY

58394-0024-03 2000 IU KIT NTHA SOLYX

OFUSE TH EWY58394-0023-03

1000 IU KIT NTHA SOLYXOFUSE TH EWY

58394-0022-03 500 IU KIT NTHA SOLYX

OFUSE TH EWY58394-0015-01

250 IU KIT NTHA SOLYXNTHA TH EWY

58394-0014-01 VIAL 2000 IU YX

NTHA TH EWY58394-0013-01

VIAL 1000 IU YXNTHA TH EWY

58394-0012-01 VIAL 500 IU YX

NTHA TH EWY

00053-7656-05

VIAL 250 IU YX

TE-P CSL BEHRING 00053-7656-04

VIAL 1500 IU MONOCLAATE-P TE-P CSL BEHRING

00944-2933-01 VIAL 1000 IU MONOCLAATE-P

HEMOFIL M TER XBA00944-2932-01

VIAL 1700 IU HEMOFIL M TER XBA

00944-2931-01 VIAL 1000 IU

HEMOFIL M TER XBA00944-2930-01

VIAL 500 IU HEMOFIL M TER XBA

00053-6223-02

VIAL 250 IU

MONONINE CSL BEHRING

58394-0636-03

VIAL 1000 IU

T THEWY58394-0635-03

VIAL 2000 IU BENEFIX RT THEWY

58394-0634-03 VIAL 1000 IU BENEFIX R

T THEWY58394-0633-03

VIAL 500 IU BENEFIX RT THEWY

68516-3200-05

VIAL 250 IU BENEFIX R

OFILNINE SD GRIFOLS 68516-3203-02

VIAL 1700 IU PROFILNINE SD GRIFOLS

68516-3202-02 VIAL 1500 IU PR

OFILNINE SD GRIFOLS 68516-3201-01

VIAL 1000 IU PROFILNINE SD GRIFOLS

64193-0244-02 VIAL 500 IU PR

BEBULIN TER XBA68516-3603-03

VIAL 500 IU ALPHANINE SD GRIFOLS

68516-3602-02 VIAL 1500 IU

ALPHANINE SD GRIFOLS 68516-3601-02

VIAL 1000 IU ALPHANINE SD GRIFOLS

63833-0386-02

VIAL 500 IU

A CSL BEHRING VIAL 500 IU CENTRK

RUTCAFUNAMREBMUNCDNEZISNOITPIRCSED

Coagulation Products

J7185

*EDOCRE

J7185

J7185J7185J7185J7185J7185J7185J7185J7185

J7190J7190

ts

oduc

rtio

n P

oagu

la C

J7190J7190J7190J7190J7190

J7194J7194J7194J7193 J7193J7193

J7193

J7195J7195J7195J7195

J7194 J7194J7194

J3590

TE odes should b ll c*A

AATE NASAL SPRSTIMAP RIASTTAP

A CENTRK

Y . eryvider and the paoeen the prwi�ed beter be v

1.5 ML AAY NASAL SPR1000 M

A 500 IU

00053-6871-00 CSL BEHRING 63833-0891-51

L CSL BEHRING

63833 0386 02 VIAL MG

CSL BEHRING VIAL

J3490J1680J3590

b h h eri�es V

du d o u od Pr odu d Pr o du od u d du d FFF

Pl hl d fd h l h

anufacturer and receipt s product pedigree from the m

uc tyyyct Saf tyeee yetct Saf yytyuc etct Saf non o s ati n ins FF vs InnoF’

f f

vides accurate product lot tracking and recall Pro

by the h

alidate vider to v healthcare pro

n el.e channe our saf

ected within foti�cation to those aff

our hours. ithin f

7

IM

I

M 67467-0843-02 J1568

*

MMUNE GLOBULIN (HUMAN) LYOPHILIZED

MUNE GLOBULIN (HUMAN) LIQUID

Immune Globulins

J1568

A APHARMTTAPHARMOC

68209-0843-01

VIAL 2 5 GM GAATTA

M

J1568

AAPHARMTTAPHARMOC

67467-0843-01

VIAL 1 GM GAATTA

M

J1559

AAPHARMTTAPHARMOC

44206-0455-10

VIAL 1 GM GAATTA

A

J1559

CSL BEHRING

44206-0454-04

VIAL 10 GM ZENTR

A

J1559

CSL BEHRING

44206-0452-02

VIAL 4 GM ZENTR

A

J1559

CSL BEHRING

44206-0451-01

VIAL 2 GM ZENTR

A

1

CSL BEHRING

13533-0800-24

VIAL 1 GM ZENTR

C 651J

1

GRIFOLS

13533-0800-71

VIAL 20 GM -MUNEX

C 651J

1

GRIFOLS

13533-0800-20

VIAL 10 GM -MUNEX

C 651J

1

GRIFOLS

13533-0800-15

VIAL 5 GM -MUNEX

C 651J

1

GRIFOLS

13533-0800-12

VIAL 2.5 GM -MUNEX

C 651J

J1557

GRIFOLS

64208-8234-03

VIAL 1 GM -MUNEX

APLEX

J1557

BPL

64208-8234-02

VIAL 10 GM MM

APLEX

J1561

BPL

76125-0900-20

VIAL 5 GM MM

AKED

J1561

KEDRION

76125-0900-10

VIAL 20 GM MM

AKED

J1561

KEDRION

76125-0900-50

VIAL 10 GM MM

AKED

J1561

KEDRION

76125-0900-25

VIAL 5 GM MM

AKED

J1561

KEDRION

76125-0900-01

VIAL 2.5 GM MM

AKED

J1569

KEDRION

00944-2700-07

VIAL 1 GM MM

GARD LIQUID

J1569

TER XBA

00944-2700-06

VIAL 30 GM AMM

GARD LIQUID

J1569

TER XBA

00944-2700-05

VIAL 20 GM AMM

GARD LIQUID

J1569

TER XBA

00944-2700-04

VIAL 10 GM AMM

GARD LIQUID

J1569

TER XBA

00944-2700-03

VIAL 5 GM AMM

GARD LIQUID

J1569

TER XBA

00944-2700-02

VIAL 2.5 GM AMM

GARD LIQUID

J1560

TER XBA

13533-0635-12

VIAL 1 GM AMM

AN S/D

J1460

GRIFOLS

13533-0635-04

VIAL 10 ML ASTTAN S/D M

AN S/D

J1572

GRIFOLS

61953-0005-03

VIAL 2 ML ASTTAN S/D M

A 10% DIF

J1572

GRIFOLS

61953-0005-02

VIAL 20 GM MMBOGA

A 10% DIF

J1572

GRIFOLS

61953-0005-01

VIAL 10 GM MMBOGA

A 10% DIF

J1572

GRIFOLS

61953-0004-05

VIAL 5 GM MMBOGA

A 5% DIF

J1572

GRIFOLS

61953-0004-04

VIAL 20 GM MMBOGA

A 5% DIF

J1572

GRIFOLS

61953-0004-03

VIAL 10 GM MMBOGA

A 5% DIF

J1572

GRIFOLS

61953-0004-02

VIAL 5 GM MMBOGA

A 5% DIF

J1566

GRIFOLS

00944-2658-04

VIAL 2.5 GM MMBOGA

G/ML)

J1566

TER XBA

00944-2656-03

VIAL 10 GM GARD S/D (IGA

9

53270-0125-02 ARIZIG

R

Hyperimmune Globulins

ANTI-THYMOCYTE GLOBULIN

BOTULISM IGIV (HUMAN) (BIG-IV)

CYTOMEGALOVIRUS IMMUNE GLOBULIN INTRAVENOUS (HUMAN)

HEPATITIS B IMMUNE GLOBULIN

RABIES IMMUNE GLOBULIN

RHO(D) IMMUNE GLOBULIN

TETANUS IMMUNE GLOBULIN

VARICELLA ZOSTER IMMUNE GLOBULIN

UTCAFUNAMREBMUNCDNEZISNOITPIRCSED

GENT EMER

13533-0634-02

VIAL 125 UNIT VVARIZIG

T S/D GRIFOLS

53270-3000-01

RINGE 250 UNIT SYTEPERYH

WINRHO SDF ANGENE C53270-3100-01

G 15000 IU 3000 MCWINRHO SDF ANGENE C

53270-3500-01 G 5000 IU 1000 MC

WINRHO SDF ANGENE C53270-3300-01

G 2500 IU 500 MCWINRHO SDF ANGENE C

44206-0300-10 G 1500 IU 300 MC

C CSL BEHRING 44206-0300-01

RINGE/10 PK G SY300 MCLAYRHOPHC CSL BEHRING

00562-7805-25 RINGE G SY300 MCLAYRHOPH

M KEDRION 00562-7805-05

RINGE/25 PK G 1 ML SY300 MCRHOGAM KEDRION

00562-7805-01 RINGE/5 PK G 1 ML SY300 MCRHOGA

M KEDRION 00562-7806-35

RINGE G 1 ML SY300 MCRHOGAM KEDRION

00562-7806-05 RINGE/25 PK G 1 ML SY50 MCMICRHOGA

M KEDRION 00562-7806-01

RINGE/5 PK G 1 ML SY50 MCMICRHOGAM KEDRION

13533-0631-02 RINGE G 1 ML SY50 MCMICRHOGA

PERRHO S/D GRIFOLS 13533-0631-06

RINGE G 1 ML SY300 MCYHPERRHO S/D GRIFOLS

13533-0618-10

RINGE G/0.17 ML SY50 MCYH

AB S/D GRIFOLS 13533-0618-02

VIAL 10 ML 150 IU/ML PERRYHAB S/D GRIFOLS

13533-0636-05

VIAL 2 ML 150 IU/ML PERRYH

PERHEP B S/D GRIFOLS 13533-0636-02

VIAL 5 ML YHPERHEP B S/D GRIFOLS

13533-0636-03 RINGE 1 ML SYYH

PERHEP B S/D GRIFOLS 53270-0051-01

RINGE 0.5 ML SYYHM B ANGENE C

53270-0052-01 VIAL 5 ML GAAHEP

M B ANGENE C

44206-0532-11

VIAL 1 ML GAAHEP

M CSL BEHRING

68403-1100-06

VIAL 2.5 GM OGATTOGAYC

BIG MBL

58468-0080-01

VIAL 100 MG YBAB

OBULIN VENSANOFI A AVENTISVIAL 25 MG MOGLYTH

tion

acJ7511

*EDOCRE

NTIS

rei

n F

otrla

sma

Pm

in /

P

903719037190371

J1571 or J1573J1571 or J1573

J0850

J7511 NTIS

lbum

m

une

Glo

bulin

s |

A

J2790J2790 J2788J2788J2788J2790J2788

9037590375

imm

yp

erH

90396

J1670

J2792J2792J2792J2792J2791J2791J2790

ALBUMIN 5% 67467-0623-03 P9045

*

Albumin / Plasma Protein Fraction

tinuedonc. err. yvider and the paoeen the prwi�ed beterodes should be vll c*A

P9045P9045P9045P9047P9047P9045P9045P9047P9047P9045P9045P9047P9047P9045P9045P9047P9047P9045

AAPHARMTTAPHARMOCAAPHARMTTAPHARMOCAAPHARMTTAPHARMOCAAPHARMTTAPHARMOC

GRIFOLSGRIFOLSGRIFOLSGRIFOLSCSL BEHRING CSL BEHRING CSL BEHRING CSL BEHRING CSL BEHRING CSL BEHRING CSL BEHRING CSL BEHRING KEDRIONKEDRIONKEDRION

68209-0623-0368209-0623-0267467-0623-0268516-5216-02 68516-5216-01 68516-5214-02 68516-5214-01 44206-0251-10 44206-0251-05 44206-0310-50 44206-0310-25 00053-7680-33 00053-7680-32 00053-7670-3200053-7670-3176125-0784-1076125-0784-2576125-0785-25

500 ML 500 ML250 ML250 ML 100 ML 50 ML 500 ML 250 ML 100 ML50 ML500 ML250 ML 100 ML50 ML 500 ML250 ML100 ML50 ML250 ML

ALBUMIN 5%ALBUMIN 5%ALBUMIN 5%ALBUTEIN 25% ALBUTEIN 25%ALBUTEIN 5% ALBUTEIN 5%

X 25% ALBURX 25% ALBURX 5% ALBURX 5% ALBUR

ALBUMINAR 25% ALBUMINAR 25% ALBUMINAR 5%ALBUMINAR 5%ALBUKED 25% ALBUKED 25% ALBUKED 5%

EDOCRERUTCAFUNAMREBMUNCDNEZISNOITPIRCSED

9

als

vir AL

A

9065649281-0014-50 ONE

*

TE 5% 13533-0613-25 P9043

*

continued

n�uenza Vaccines & Antivirals

15

P9043P9047P9047P9046P9045 P9041P9047P9047P9047P9047P9045P9045P9047P9047P9047P9047

GRIFOLSGRIFOLSGRIFOLSGRIFOLSGRIFOLSGRIFOLSGRIFOLSKEDRION

TERXBATERXBATERXBATERXBATERXBA

AAPHARMTTAPHARMOCAAPHARMTTAPHARMOCAAPHARMTTAPHARMOCAAPHARMTTAPHARMOC

00026-0613-20 13533-0692-71 13533-0692-20 13533-0692-16 13533-0685-25 00026-0685-20 76179-0025-0100944-0493-0200944-0493-0100944-0490-0200944-0491-0200944-0491-0168209-0643-0267467-0643-02 68209-0643-0167467-0643-01

250 ML PPF50 ML PPF100 ML 50 ML20 ML 250 ML 50 ML50 ML 100 ML50 ML50 ML500 ML250 ML100 ML 100 ML 50 ML50 ML

ANAATE 5% LASMTE 5% ANAATE 5% LASM

LASBUMIN 25% LASBUMIN 25% LASBUMIN 25% LASBUMIN 5% LASBUMIN 5% EDBUMIN 25%EXBUMIN 25%EXBUMIN 25%

TE 25%UMINAATE 25%TE 5%UMINAATE 5%TE 5%UMINAATE 5%

LBUMIN 25%LBUMIN 25%LBUMIN 25%LBUMIN 25%

Albumin / Plasma Protein Fraction EDOCRERUTCAFUNAMREBMUNCDNEZISNOITPIRCSED

Q2038ASTEUR SANOFI P

49281-0394-15 0.5 ML PFS UZ

ONE 90658

ASTEUR SANOFI P66521-0117-02

VIAL 5 ML 10 DS UZUVIRIN

90658/Q2037TIS ARNOVVAR

66521-0117-10 0.5 ML PFS

UVIRIN 90672

TIS ARNOVVAR66019-0301-10

VIAL 5 ML 10 DS ALENT

90686MEDIMMUNE

19515-0894-52 ER YAAYANASAL SPR0.2 ML INTRADRIVVALENT UMIST QU

ALENT 90688

OSMITHKLINE XGLA19515-0891-11

0.5 ML PFS ADRIVVALENT AL QUVVAL QUULAAVALENT

90658/Q2036OSMITHKLINE XGLA

19515-0893-07 VIAL 5 ML 10 DS ADRIVVALENT AL QUVVAL QUULAAV

AL 90661

OSMITHKLINE XGLA63851-0113-01

5 ML MDV VVAL ULAAVX

90673TIS ARNOVVAR

TBD 0.5 ML PFS AVVAUCELLV

OK 90686

TEIN SCIENCES OPR58160-0901-52

0.5 ML SDV UBLALENT

90656OSMITHKLINE XGLA

33332-0114-01 0.5 ML PFS ADRIVVALENT ARIX QUU

URIA 90658/Q2035

BIOCSL 33332-0114-10

0.5 ML PFS FLURIA BIOCSL VIAL 5 ML 10 DS FL

-FLUENZA VACCINES 2014EDOCRERUTCAFUNAMREBMUNCDNEZISNOITPIRCSED

tivnci

nes

& A

acVue

nza

PL PL PL KE FL FL BUBUBUAL AL AL

n�

tion

| I

acrei

n F

otra

P

AF

PL

I

INF

PLPL PL PL

AF

lasm

a lb

umin

/ P

A

UFLUFLU FLU FLU FLUFLUFLUFLUFLUFLUFL

AF

AL SUSP

ANTIVIRALS

vider and th oeen the prwi�ed beterodes should be vll c*A

6 MG/M U ORMIFLATTAU 75 MG MIFLATTA

ALENT 0.5 ML ADRIVVALENT ONE QUUZFLALENT 0.5 ML ADRIVVALENT ONE QUUZFLALENT 0.25 ML ADRIVVALENT ONE QUUZFLALENT 5 ML 10 ADRIVVALENT ONE QUUZFL

AL 0.1 ML ADERMONE INTRUZFLONE HIGH-DOSE 0.5 ML UZFL

000 . err. y he pa

000 ML

492

AP 10 PK C

492 SDV

492 PFS

492 L PFS

492 VIAL 0 DS

492 PFS PFS

004-0820-09 GENENTECH 004-0800-85 GENENTECH

281-0414-10 SANOFI P281-0414-50 SANOFI P281-0514-25 SANOFI P281-0621-15 SANOFI P281-0709-55 SANOFI P281-0395-65 SANOFI P

J8499J8499

TECH

90686

TECH

90686 ASTEUR I P

90685ASTEUR I P

90688ASTEUR I P

90654ASTEUR I P

90662ASTEUR I PASTEUR I P

EHTKCIPUOY

yF.Mwww|(800) 843-7477

PUOYYTITNAUQ

om.ccineacluVF

EWETADEHTKCI

REVILED

10

TUBERSOL 49281-0752-21

R

Other Vaccines

ASTEU SANOFI P49281-0820-10

TEST VIAL 10 1 ML OID ADS UPS ASTEU SANOFI P

49281-0215-15 0.5 ML SDV/10 PK XOTANUS TTANUS TE

C ASTEU SANOFI P49281-0215-10

10 PFS/BX ATENIVVAC ASTEU SANOFI P

00006-4133-41 10 SDV/BX ATENIVVA

TD ABSORBED CK MER00006-4047-20

10 PK SDV VIRUS, LIVE CK MER

00006-4047-41 TUBES/25 PK 2 ML AAVIRUS, LIVE TTAOTEQ RAATEQ RTTAOR

VIRUS, LIVE CK MER00006-4981-00

TUBES/10 PK 2 ML AAVIRUS, LIVE TTAOTEQ RAATEQ RTTAORX HB PED/ADOLESC CK MER

00006-4094-09 G/0.5 ML 10 PK 5 MCAOMBIVVAREC

T CK MER00006-4995-41

G PFS/6 PK 10 MCX HB ADUL LT AOMBIVVARECT CK MER

00006-4992-00 VIAL/10 PK G 10 MCX HB ADUL LT AOMBIVVAREC

SIS CK MER00006-4093-09

G SDV 40 MCYX HB DIAL LYAOMBIVVARECX HB PED/ADOLESC CK MER

00006-4995-00 G/6 PK PFS 5 MCAOMBIVVAREC

T CK MER63851-0501-01

G/SDV 10 MCX HB ADUL LT AOMBIVVARECABIES TIS ARNOVVAR

00005-1971-02 UENT W/DILSDV T RVERABAAVERR

VNAR 13 PFIZER 00006-4739-00

PFS/10 PK PREX 23 CK MER

00006-4943-00 VIAL 2.5 ML APNEUMOVVA

X 23 CK MER49281-0510-05

0.5 ML SDV/10 PK APNEUMOVVACEL ASTEU SANOFI P

00006-4897-00 SDV/5 PK APENTTA

X HIB CK MER00006-4681-00

0.5 ML SDV/10 PK APEDVVAMMR II MEASLES MUMPS CK MER

00006-4673-00 0.5 ML SDV/10 PK

X CK MER49281-0489-01

0.5 ML SDV/10 PK AMERUVVAMENOMUNE ASTEU SANOFI P

49281-0589-05 SDV

A ASTEU SANOFI P42515-0001-01

SDV/5 PK TRCMENAO TIS ARNOVVAR

49281-0860-10 0.5 ML PFS IXIAR

VIRUS ASTEU SANOFI P49281-0250-51

5 ML MDV IPOL POLIO ABIES ASTEU SANOFI P

00006-4045-00 UENT W/DIL1 SDV X IM RAIMOVVA

ASIL HPV CK MER00006-4045-41

VIAL 0.5 ML GARDASIL HPV CK MER

49281-0225-10 10 0.5 ML SDV GARD

OID ASTEU SANOFI P49281-0286-10

10 SDV PF PEDS XOTANUS TTANUS TEDIPHTHERIA AND CEL ASTEU SANOFI P

49281-0400-10 10 SDV/BX AAPTTAD

AP) ASTEU SANOFI P49281-0400-15

10 SDV/BX TDCEL (AADAP) ASTEU SANOFI P

49281-0545-05 5 PFS/BX TDCEL (AAD

THIB ASTEU SANOFI PUENT W/DILG 10 MCCAUTCAFUNAMREBMUNCDNEZISNOITPIRCSED

90715

*

90648UR UR

EDOCRE

cine

sc90733

90734UR

90738UR

9071390675

UR

90649UR

906499071490700

UR

90715UR

90715UR UR

acVth

er

O

90740 or 90747

90744 90746906759067090732907329069890647

UR

9070790706

8658090703

R

90714 R

90714R

90714R

906809068090744

90743 or 90746

90743 or 90746

90740 or 90747

X 00006-4963-00 90736

90736CK MER

00006-4963-41 SDV AVVAAAVOSTTAZ

X 90716

CK MER00006-4827-00

SDV/10 PK AVVAAAVOSTTAZX

90716CK MER

00006-4826-00 0.5 ML SDV/10 PK AARIVVAVVARIV

X 90633

CK MER00006-4831-41

0.5 ML SDV AARIVVAVVARIVA

90633CK MER

00006-4095-09 25 U/0.5 ML SDV/10 PK TTA QAVVA

A 90632

CK MER00006-4096-09

25 U/1 ML PFS/6 PK TTA QAVVAA

90691CK MER

49281-0790-51 50 U/1 ML PFS/6 PK TTA QAVVA

PHOID 90691

ASTEUR SANOFI P49281-0790-20

0.5 ML/PFS YTVI PHIM YTPHOID

86580ASTEUR SANOFI P

49281-0752-22 10 ML MDV YTVI PHIM YT

TUBERSOL ASTEUR SANOFI PTEST VIAL 50 5 ML

moc.eniccaVulFyM.www|moc.sesirpretneFFF.www|3334-814)008(xaF|7747-348)008(:REDROOT

. err. yvider and the paoeen the prwi�ed beterodes should be vll c*A

11

Surg

ical

Sea

lant

s |

Oth

er S

peci

alty

Pro

duct

s

Surgical Sealants

Disposable Containers DESCRIPTION MANUFACTURER

Other Specialty Biopharmaceuticals DESCRIPTION SIZE NDC NUMBER MANUFACTURER CODE*

Syringes DESCRIPTION

Complimentary Support Material DESCRIPTION TO ORDER OR SUBSCRIBE OR FOR MORE INFORMATION

DESCRIPTION SIZE NDC NUMBER MANUFACTURER CODE*

SHARPS COMPLIANCE SHARPS COMPLIANCE SHARPS COMPLIANCE SHARPS COMPLIANCE SHARPS COMPLIANCE SHARPS COMPLIANCE SHARPS COMPLIANCE

1-QUART SHARPS RECOVERY SYSTEM1.5-QUART SHARPS RECOVERY SYSTEM1-GALLON SHARPS RECOVERY SYSTEM2-GALLON SHARPS RECOVERY SYSTEM3-GALLON SHARPS RECOVERY SYSTEM5-GALLON SHARPS RECOVERY SYSTEM for use with non-sharps biohazard waste only20-GALLON SHARPS RECOVERY SYSTEM

BERINERT 500 IU VIAL 63833-0825-02 CSL BEHRING J0597 THROMBATE III 500 IU VIAL 13533-0603-20 GRIFOLS J7197

Specialty Pharmaceuticals DESCRIPTION SIZE NDC NUMBER MANUFACTURER CODE*

ATRYN 1750 IU VIAL 42976-0121-02 rEVO Biologics J7196 CLOLAR 20 MG/ML VIAL 58468-0100-01 SANOFI AVENTIS J9027 CUBICIN 500 MG SDV/10 PK 67919-0011-01 CUBIST J0878 HEMABATE 1 ML VIAL/10 PK 00009-0856-08 PFIZER J3490 MOZOBIL 20 MG/1.2 ML VIAL 58468-0140-01 SANOFI AVENTIS J2562 ZALTRAP 5 ML VIAL 00024-5840-01 SANOFI AVENTIS J9400 ZALTRAP 10 ML VIAL 00024-5841-01 SANOFI AVENTIS J9400

AVAILABLE UPON REQUEST

BIOSUPPLY TRENDS QUARTERLY MAGAZINEIG LIVING! MAGAZINEBIOSUPPLY TRENDS eNEWSLETTERPRODUCT REFERENCE CHARTSSEASONAL FLU POSTERFLU MYTHS AND FACTS BROCHUREeCOMMUNICATION ALERTSEDUCATIONAL TELECONFERENCESIVIG REIMBURSEMENT CALCULATORPRODUCT CATALOG

All complimentary support materials are available to order on the FFF website.

TO ORDER: (800) 843-7477 | Fax (800) 418-4333 | www.FFFenterprises.com | www.MyFluVaccine.com

*All codes should be veri#ed between the provider and the payer.

TISSEEL 2 ML VHSD VALUPAK 00944-4201-04 BAXTER J3590, C9399 TISSEEL 4 ML VHSD VALUPAK 00944-4201-08 BAXTER J3590, C9399 TISSEEL 10 ML VHSD VALUPAK 00944-4201-12 BAXTER J3590, C9399 TISSEEL VHSD KIT 2 ML 00944-4201-03 BAXTER J3590, C9399 TISSEEL VHSD KIT 4 ML 00944-4201-07 BAXTER J3590, C9399 TISSEEL VHSD KIT 10 ML 00944-4201-11 BAXTER J3590, C9399

12

SaSaSaSaleleleles s s s SuSuSuSupppppppporororort t t t anananand d d d WoWoW w!w! C Cusustotomemer CaaCaare™

FrF om our in-house teams of cususstomem r cacacareree

rereprpresesenentatatit veves,s,, a a advdvd isisorors s anand d adadvovocacacatetes,s,s t t to o ououour r r

nanatitiononalal ! !eleld d teteamam o of f tetet rrrititi ororory y mamananan gegersrsrs, , , ,

ththerere e isis always a responsive, dedicated d exexpepertrt

to take care of f yourur n neeeedsds..

OuOur r WoWow!w!!! C C C Cusussu tototot memem r r CaCarere

professionals are here t to o susuppp ort you.

E mergency ordering and shipping 24/7/7/363655

On-caallll p pharmacist

Veri!ed Electtroronic Pedigree™ for every order

Lot-Track™ tracking and recall noti!cation

BioSupply™ online ordering and reporting

Specialty publicatioons for current industry

and inventory newss

Expert advisors

Patient advocates

Nationwide, robust sales force of professionals

SupportInfusion Advisor Line

Our infusion specialists will answer

your questions about the principles

of intravenous and subcutaneous

infusion therapy, cost-effective care

and improving patient outcomes.

Pharmacy Advisor Line

Our on-call pharmacists have the

expertise to answer your product

or dosing questions about every

drug provided by FFF.

Reimbursement Advisor Line

Our reimbursement specialists are

ready to resolve your questions and

guide you through the complexities

of biopharmaceutical reimbursement.

P

O

R

O

Advisor Lines

FFF ENTERPRISES

ResourcesBBBEEYYYYYOOOOONNNNNDDDDD DDDIISS N,,ISTRIBUTTIONN FFFFF ENTERPRISESS iiss pleaaaassseed ttooo pprroovviiddeee mmmeeeaannniiinnnggggffffuuuullll ccccoooommmmmmmmuuuunnnniiiiccccaaaa----

ttttiooonnss ffoor ppppaaa aalltthhccaarree pprroovviddeerss,, bbbrriinnggggiiiinngggggg ffffooooccccuuuussss aaanndd innsigghht into the complexities off tthhee aaaaaaatttiieennttss aanndd hheeaall

ssppppeeeeciaaallltttyyy ccaalllss mmaarrrrkkkeetttpppplllaaaaccccee,, aass wweellll aass vvaaaallluuuaaabbbblleeee rrrreeesssoouuuurrrcceess ttoo hheelpp oourr cuustommerrs pprroovviiddee yyyyyyy pppppharmaceutica

ttthheeee bbbeesstt ir patients – it’s one more way wwee’rree sstt ccaarree ffoorr tthheiir HHeeeellllppiiinnngggg HHHeeeeaaaalllltttthhhhccccaaaarrrreeee CCCCaaaarreee®®!!!

This complimentary magazine published by FFF is the denitive source for news, trends and information for the biopharmaceutical marketplace. BSTQ earned top honors with several 2013 MarCom Awards.

> Subscribe and view our online edition at: www.BSTQuarterly.com

IG Living! is the only magazine that delivers comprehensive healthcare and immune globulin information, community and reimbursement news, and resources for successful living directly to immune globulin patients and their healthcare providers.

> Subscribe and view our online edition at: www.IGLiving.com

FFF’s award-winning enewsletter, BioSupply Trends, is a bi-monthly publication to update customers, analysts and others who seek insight into the complexities of the specialty pharmaceuticals marketplace.

> Subscribe online at: www.FFFenterprises.com.

BioSupply Trends eNewsletter

IG Living! Magazine

BioSupply Trends Quarterly Magazine

14

Flu Myths and Facts Brochure

eCommunication Alerts

Product Reference Charts

• Seasonal In!uenza Vaccine • Immune Globulin• Hyperimmune Globulin• Anti-Inhibitor Factor VIIa & IX• Factor VIII

FFF’s complimentary Product Reference Charts are highly valued educational resources for comparative product information.

> Customers can order the following charts on the FFF website:

Seasonal Flu Poster

FFF provides complimentary seasonal !u posters in English and Spanish to our customers to help them plan and promote their !u vaccination clinics.> Posters may be ordered on the FFF website.

Our complimentary patient-focused brochures demystify the seasonal !u virus and highlight the bene"ts of receiving the vaccine. Because the !u is preventable, and the vaccine changes each year, it’s important to dispel the myths about the disease and provide information about how people can best protect themselves and their loved ones.

> Myths and Facts Brochures may be ordered on the FFF website.

Updates on seasonal and pandemic in!uenza conditions, marketplace news and information, plus ecommunications tailored to meet the needs of individual customer groups, as well as alerts that advocate for patients and patient organizations.

Additional Resources

Experts focus on trending topics and answer questions that are prevalent in the biopharmaceuticals marketplace.

Educational Monthly Teleconferences IVIG Reimbursement Calculator

Find the current reimbursement rate for IVIG, based on the CMS published ASP rates for Physician O$ce and Hospital Outpatient facilities.

> Available at: www.FFFenterprises.com

15

WHAT YOU SHOULD KNOW ABOUT HEMOLYTIC DISEASE OF THE NEWBORN (HDN)

What is hemolytic disease of the newborn (HDN)?

sensitization or alloimmunization

COOMBS TEST

QUESTIONS AND ANSWERS

Please see adjacent page for brief summary of full prescribing information.

Reactions to RhO(D) immune globulin (human) are infrequent in RhO(D)-negative individuals and consist primarily of slight soreness at the site of injection and slight temperature elevation. While sensitization to repeated injections of human immunoglobulin is extremely rare, it has occurred.

r

p

p

c

t

p

Printed in USA. December 2013 HY36-1213

HyperRHO® S/D Full DoseRho(D) Immune Globulin (Human)Solvent /Detergent Treated

BRIEF SUMMARYCONSULT PACKAGE INSERT FOR FULL PRESCRIBING

INFORMATIONFOR INTRAMUSCULAR INJECTION ONLY

INDICATIONS AND USAGEPregnancy and Other Obstetric ConditionsRho(D) Immune Globulin (Human) — HyperRHO® S/D Full Doseis recommended for the prevention of Rh hemolytic disease of thenewborn by its administration to the Rho(D) negative mother within72 hours after birth of an Rho(D) positive infant, providing thefollowing criteria are met:1. The mother must be Rho(D) negative and must not already be

sensitized to the Rho(D) factor.2. Her child must be Rho(D) positive, and should have a negative

direct antiglobulin test (see PRECAUTIONS).If HyperRHO S/D Full Dose is administered antepartum, it isessential that the mother receive another dose of HyperRHO S/DFull Dose after delivery of an Rho(D) positive infant.If the father can be determined to be Rho(D) negative,HyperRHO S/D Full Dose need not be given.HyperRHO S/D Full Dose should be administered within 72 hoursto all nonimmunized Rho(D) negative women who have undergonespontaneous or induced abortion, follow ing ruptured tubalpregnancy, amniocentesis or abdominal trauma unless the bloodgroup of the fetus or the father is known to be Rho(D) negative. Ifthe fetal blood group cannot be determined, one must assumethat it is Rho(D) positive, and HyperRHO S/D Full Dose should beadministered to the mother.TransfusionHyperRHO S/D Full Dose may be used to prevent isoimmuni -zation in Rho(D) negative individuals who have been transfusedwith Rho(D) positive red blood cells or blood componentscontaining red blood cells.

CONTRAINDICATIONSNone known.

WARNINGSHyperRHO S/D Full Dose is made from human plasma.Products made from human plasma may contain infectiousagents, such as viruses, and, theoretically, the Creutzfeldt-Jakob Disease (CJD) agent that can cause disease. The riskthat such products will transmit an infectious agent has beenreduced by screening plasma donors for prior exposure tocertain viruses, by testing for the presence of certain currentvirus infections, and by inactivating and/or removing certainviruses. Despite these measures, such products can stillpotentially transmit disease. There is also the possibility thatunknown infectious agents may be present in such products.Individuals who receive infusions of blood or plasma productsmay develop signs and/or symptoms of some viral infections,particularly hepatitis C. ALL infections thought by a physicianpossibly to have been transmitted by this product should bereported by the physician or other healthcare provider toGrifols Therapeutics Inc. [1-800-520-2807]. The physician should discuss the risks and benefits of thisproduct with the patient, before prescribing or administering itto the patient.NEVER ADMINISTER HYPERRHO S/D FULL DOSEINTRAVENOUSLY. INJECT ONLY INTRAMUSCULARLY. NEVERADMINISTER TO THE NEONATE.

Rho(D) Immune Globulin (Human) should be given with caution topatients with a history of prior systemic allergic reactions followingthe administration of human immunoglobulin preparations.The attending physician who wishes to administer Rho(D)Immune Globulin (Human) to persons with isolated immuno -globulin A (IgA) deficiency must weigh the benefits of immuni -zation against the potential risks of hypersensitivity reactions.Such persons have increased potential for developing antibodiesto IgA and could have anaphylactic reactions to subsequentadministration of blood products that contain IgA.As with all preparations administered by the intramuscular route,bleeding complications may be encountered in patients withthrombocytopenia or other bleeding disorders.

PRECAUTIONSGeneralA large fetomaternal hemorrhage late in pregnancy or followingdelivery may cause a weak mixed field positive Du test result. Ifthere is any doubt about the mother’s Rh type, she should begiven Rho(D) Immune Globulin (Human). A screening test todetect fetal red blood cells may be helpful in such cases.If more than 15 mL of D-positive fetal red blood cells are presentin the mother’s circulation, more than a single dose ofHyperRHO S/D Full Dose is required. Failure to recognize thismay result in the administration of an inadequate dose.Although systemic reactions to human immunoglobulinpreparations are rare, epinephrine should be available fortreatment of acute anaphylactic reactions.Drug InteractionsOther antibodies in the Rho(D) Immune Globulin (Human)preparation may interfere with the response to live vaccines suchas measles, mumps, polio or rubella. Therefore, immunizationwith live vaccines should not be given within 3 months afterRho(D) Immune Globulin (Human) administration.Drug/Laboratory InteractionsBabies born of women given Rho(D) Immune Globulin (Human)ante partum may have a weakly positive direct antiglobulin test atbirth.Passively acquired anti-Rho(D) may be detected in maternalserum if antibody screening tests are performed subsequent toantepartum or postpartum administration of Rho(D) ImmuneGlobulin (Human).Pregnancy Category CAnimal reproduction studies have not been conducted withHyperRHO S/D Full Dose. It is also not known whetherHyperRHO S/D Full Dose can cause fetal harm whenadministered to a pregnant woman or can affect reproductioncapacity. HyperRHO S/D Full Dose should be given to a pregnantwoman only if clearly needed.Pediatric UseSafety and effectiveness in the pediatric population have not beenestablished.

ADVERSE REACTIONSReactions to Rho(D) Immune Globulin (Human) are infrequent inRho(D) negative individuals and consist primarily of slightsoreness at the site of inject ion and slight temperature elevation.While sensitization to repeated injections of human immuneglobulin is extremely rare, it has occurred. Elevated bilirubin levelshave been reported in some individuals receiving multiple dosesof Rho(D) Immune Globulin (Human) following mismatchedtransfusions. This is believed to be due to a relatively rapid rate offoreign red cell destruction.

Grifols Therapeutics Inc.Research Triangle Park, NC 27709 USAU.S. License No. 1871 08941119-BS

© 2013 Grifols Inc. All rights reserved. Printed in USA. December 2013 HY36-1213

First FVIII/VWF product in the US stable for 3 years, up to the expiration date printed, when stored at or below 77°F (25°C). Do not freeze.

Please see brief summary of Alphanate® Full Prescribing Information below.

For more information: Grifols Inc.Customer Service: 888 325 8579 Fax: 323 441 7968

Grifols Biologicals Inc.5555 Valley Boulevard, Los Angeles, 90032 CA - USA Tel. 888-GRIFOLS (888 474 3657)

www.grifolsusa.com

The Power of FVIII/VWF Complex

Convenient Room Temperature Storage

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use Alphanate Antihemo-philic Factor/von Willebrand Factor Complex (Human) safely and effectively. See Full Prescribing Information for Alphanate.

ALPHANATE (ANTIHEMOPHILIC FACTOR/VON WILLEBRAND FACTOR COMPLEX [HUMAN]) Sterile, lyophilized powder for injection

For Intravenous Use Only

Initial U.S. Approval: 1978

INDICATIONS AND USAGEAlphanate is an Antihemophilic Factor/von Willebrand Factor Complex (Human) indicated for:

CONTRAINDICATIONS

WARNINGS AND PRECAUTIONS

ADVERSE REACTIONS

To report SUSPECTED ADVERSE REACTIONS, contact Grifols Biologicals Inc. at 1-888-GRIFOLS (1-888-474-3657) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

USE IN SPECIFIC POPULATIONS

First FVIII/VWF product in the US stable for 3 years, up to the expiration date printed, First FVIII/VWF product in the US stable for 3 years, up to the expiration date printed,

© 2012 Grifols Biologicals Inc. All rights reserved. Printed in USA. January 2012 A803-0911

See full prescribing information for Privigen.

W

R

E

Risk factors for hemolysis include high

d

Serious a

Use only if clearly needed.

B

2 3 11:30 AM

t

l

tsseeggrrgLaLaezi SaliaVill biAA availab

0 pt

e!!

telel 0

a

0 n 4g

4I

4V

4 I

4n

4I

0 e4v4i4r4P44e

4h

40 r

0 eh

e4 t

4g0 g4i4

0 py

gd0 g: An a0 0 g0 n 40 g

gd ge gd g

0 e0 r0 u0 u4a4e4m4y-0 -0 o4d4a4e4R4Simple choicg4gu4ss o0 rgest vial size of IVIg available

t ce4

ovides the lar

e

Pr

Simple storage helf sp Occupies less sh

0 Simple administration

0 g ge gi gn0 n0 o0 c0 % I0 se 10 u gi giqu0 vial size of IVIg available

ge

g pace than two 20-g cartons for mor

tion

e v0 of0 f c0 e Ig V0 0 l0 g

gficient storage

g ef

gce gn ge gd g

Simple administration Reduces the number of vials to open and handle for infusions of 40 g or mor

tion of vials to open and handle for infusions of 40 g or mor

e ons of 40 g or mor

Important S Privigen is ind immunodefici

aise platel to r

TARNING:WWARNING:

Safety Informationapy for patients with primary immunodeficiency (PI) associated with defects in humor dicated as replacement ther

cong ed agammaglobulinemia, X-linkiency (CVID), let counts in patients with chronic immune thrombocytopenic purpur

AAND SFUNCTION Y RENAL D,THROMBOSIS

rimary immunodeficiency (PI) associated with defects in humorott-Aldrich syndromeWisk enital agammaglobulinemia,

a (ITP). bocytopenic purpur

AILURECUTE RENAL F FAILUREA

including but not limited to common v,al immunity ects in humor P . and severe combined immunodeficiencies, rome

ariable to common v Privigen is also indicated

Privigen is conwith antibodi

In patients at Ensure that p

hrombosis m T,infrequently

eit ,Hemolysisand high doseincreased risk

aindicated in patients with history of anaphylac ntr who have had hypersensitivity reactions es to IgA,

monitor uri , risk for developing acute renal failure atients with preexisting renal insufficiency or othe

even in the absence of might occur with Privigen, aseptic meningitis syndrome (AMS) may occur—

ascular or due to enhanced red blood ce av ther intr Closely monitor patients for hemolysis and hem . es

acute kidney injury or vo hemolysis k of thrombosis

ctic or severe systemic reaction to human immune gatients with IgA deficiency and antibodies to IgA P.

including blood urea nitrogen and serum creatinine; ne output and renal function, rwise predisposed are not volume-depleted and ad

atients could also experience hyperproteinemia, P. known risk factors) and/or —more frequently with high doses (2 g/kg

can develop subsequent to treatment.ation, ell sequestr Consider the relative risks and benefits before prescribing high-dose regimen for chronic ITP in patients at molytic anemia.

Monitor patients for pulmonary adverse reactions and signs of tr olume overload

and in IgA-deficient patients in patients with hyperprolinemia, globulin, A are at greater risk of severe hypersensitivity and anaphylactic reactions

discontinue if renal function deterior a nitrogen and serum creatinine;ate of infusion en at the minimum r dminister Privig

or hyponatremia;, increased serum viscosity ce hyperproteinemia,apid infusion. r

underlying inflammation,, Risk factors include non-O blood group ment. efits before prescribing high-dose regimen for chronic ITP in patients at

ansfusion-related acute lung injury (TRALI). dverse reactions and signs of tr

IgA-deficient patients. anaphylactic reactions

.ates al function deterior.acticable pr

r hyponatremia;

erlying inflammation, onic ITP in patients at

acute lung injury (TRALI).

increased risk

Privigen is de completely el

In clinical stu ele pain,pain,

and dizziness

In clinical stu ,TT,positive DA

adverse react

reatment wit TTreatment with Privigen might interfere with a patient’In patients ove

Privigen is manuegPrivigen is a r

acute kidney injury or vo , hemolysis, k of thrombosis

ansmissio he risk of trT erived from human plasma. iminated.

dies of patients being treated with Privigen for P diarrh abdominal pain,,atureated body temper ev

, Serious adverse reactions were hypersensitivity. s

dies of patients being treated with Privigen for ch increases in vomiting,, epistaxis nausea, anemia,

as aseptic meningitis syndrome (AMS). tion w

s response th Privigen might interfere with a patient’ er 65 or in any patient at risk of developing renal in

ed by CSL Behring AG and distributed by CSL Beh ufactured trademark of CSL Behring AG.gister

Monitor patients for pulmonary adverse reactions and signs of tr olume overload.

the including viruses and,,on of infectious agents

the most common adverse reactions observed I, joint chest pain, stomach discomfort, cough, hea,

and increased body temper, dizziness, fatigue, chills

the most common adverse reactions seen in >5% of subjects were headache, hronic ITP P, decreas conjugated and unconjugated bilirubin,

accines and could lead to misinterpretation of serologic testing. to live virus v do not exceed recommended dose and infuse Privigen at the minimum r, sufficiency

hring LLC.

ansfusion-related acute lung injury (TRALI). dverse reactions and signs of tr

ob disease (CJD) agent,ak the Creutzfeldt-J, eoretically

naus, fatigue, in >5% of subjects were headache pharyngolaryngeal pain,,e illness influenza-lik swelling/effusion,

.ature mper

ated body temper elev, een in >5% of subjects were headache and increased blood lactate dehydrogenase ed hematocrit,

Use in pregnant women only if clearly needed. tation of serologic testing..acticableate pr infuse Privigen at the minimum r

acute lung injury (TRALI).

cannot be gent,

back vomiting,, chills sea, urticaria, olaryngeal pain,

,atured body temperA serious . drogenase

only if clearly needed.

©2013 CSL Be ven 1020 First A

.CSLBehrwwww.CSLBehring-us.com

hring LLC A 19406-0901 USAnue, PO Box 61501, King of Prussia, P PA 19406-0901 USA

ring-us.com .Privigen.comwwww.Privigen.com PVG13-11-0038

12/2013

Privigen®Immune Globulin Intravenous (Human), 10% LiquidInitial U.S. Approval: 2007

BRIEF SUMMARY OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use Privigen safely and effectively. See full prescribing information for Privigen.

WARNING: THROMBOSIS, RENAL DYSFUNCTION AND ACUTE RENAL FAILURESee full prescribing information for complete boxed warning.

Thrombosis may occur with immune globulin products, including Privigen. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling vascular catheters, hyperviscosity, and cardiovascular risk factors.

Renal dysfunction, acute renal failure, osmotic nephrosis, and death may occur with immune globulin intravenous (IGIV) products in predisposed patients. Renal dysfunction and acute renal failure occur more commonly in patients receiving IGIV products containing sucrose. Privigen does not contain sucrose.

For patients at risk of thrombosis, renal dysfunction or renal failure, administer Privigen at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity.

------------------------------------INDICATIONS AND USAGE----------------------------------Privigen is an Immune Globulin Intravenous (Human), 10% Liquid indicated for the treatment of:

Primary humoral immunodeficiency (PI) Chronic immune thrombocytopenic purpura (ITP)-------------------------------DOSAGE AND ADMINISTRATION-----------------------------Intravenous Use Only

Indication Dose Initial InfusionRate

Maintenance Infusion Rate (as tolerated)

PI 200-800 mg/kg (2-8 mL/kg) every 3-4 weeks

0.5 mg/kg/min (0.005 mL/kg/min)

Increase to 8 mg/kg/min (0.08 mL/kg/min)

ITP 1 g/kg (10 mL/kg) for 2 consecutive days

0.5 mg/kg/min (0.005 mL/kg/min)

Increase to 4 mg/kg/min (0.04 mL/kg/min)

Ensure that patients with pre-existing renal insufficiency are not volume depleted, and discontinue Privigen if renal function deteriorates.

For patients at risk of renal dysfunction or thrombosis, administer Privigen at the minimum dose and infusion rate practicable.--------------------------------DOSAGE FORMS AND STRENGTHS-------------------------Privigen is a liquid solution containing 10% IgG (0.1 g/mL).

---------------------------------------CONTRAINDICATIONS ----------------------------------- History of anaphylactic or severe systemic reaction to human immune globulin

Hyperprolinemia (Privigen contains the stabilizer L-proline) IgA-deficient patients with antibodies to IgA and a history of hypersensitivity

------------------------------WARNINGS AND PRECAUTIONS------------------------------- IgA-deficient patients with antibodies to IgA are at greater risk of developing severe

hypersensitivity and anaphylactic reactions. Monitor renal function, including blood urea nitrogen and serum creatinine, and urine

output in patients at risk of developing acute renal failure. Thrombosis may occur with immune globulin products, including Privigen. Hyperproteinemia, increased serum viscosity, and hyponatremia may occur. Aseptic meningitis syndrome (AMS) may occur, especially with high doses or rapid

infusion. Hemolysis that is either intravascular or due to enhanced red blood cell sequestration

can develop subsequent to Privigen treatments. Risk factors for hemolysis include high doses and non-O blood group. Closely monitor patients for hemolysis and hemolytic anemia.

Monitor patients for pulmonary adverse reactions (transfusion-related acute lung injury [TRALI]).

Carefully consider the relative risks and benefits before prescribing the high dose regimen (for chronic ITP) in patients at increased risk of thrombosis, hemolysis, acute kidney injury, or volume overload.

Privigen is made from human blood and may contain infectious agents, e.g., viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent.

------------------------------------ADVERSE REACTIONS------------------------------------- PI – The most common adverse reactions, observed in >5% of study subjects, were

headache, fatigue, nausea, chills, vomiting, back pain, pain, elevated body temperature, abdominal pain, diarrhea, cough, stomach discomfort, chest pain, joint swelling/effusion, influenza-like illness, pharyngolaryngeal pain, urticaria, and dizziness. Serious adverse reactions were hypersensitivity, chills, fatigue, dizziness, and increased body temperature.

Chronic ITP – The most common adverse reactions, observed in >5% of study subjects, were headache, elevated body temperature, positive direct antiglobulin test (DAT), anemia, nausea, epistaxis, vomiting, blood bilirubin unconjugated increased, blood bilirubin conjugated increased, blood total bilirubin increased, hematocrit decreased, and blood lactate dehydrogenase increased. A serious adverse reaction was aseptic meningitis.

To report SUSPECTED ADVERSE REACTIONS, contact CSL Behring Pharmacovigilance at 1-866-915-6958 or FDA at 1-800-FDA-1088 or

www.fda.gov/medwatch.

----------------------------------DRUG INTERACTIONS---------------------------------------The passive transfer of antibodies may:

Lead to misinterpretation of the results of serological testing. Interfere with the response to live virus vaccines.

----------------------------USE IN SPECIFIC POPULATIONS--------------------------------- Pregnancy: No human or animal data. Use only if clearly needed. Geriatric: In patients over age 65 or in any patient at risk of developing renal

insufficiency, do not exceed the recommended dose, and infuse Privigen at the minimum rate practicable.

Based on November 2013 revision.

Where delivering vaccines is our mission

bioCSL, previously CSL Biotherapies, understands the

bioCSL is a trademark of CSL Limited.©2014 bioCSL Inc., 1020 First Avenue, PO Box 60446, King of Prussia, PA 19406-0446www.biocsl-us.com BCSL14-03-0004 4/2014

bioCSL has invested in one of the only high-speed

W R

ak ak

ith W

TTa

ke

e

ke Cont Cont

o echnolo RFID T

of Your o

olol

om FFFogy fr

Invento t tr tr

ory y

W

distributes evious st pr

passive RF erified Inv Ve

R ith R

Plus..

W

s – leaving you ee to focus i

fre torage location n and conditi

a FID technology y to track, tra g ogr Consig

o –ram ventory Pr

echnolo e o echnolo e

..

RFID T RFID Te

e. s on patient carod e pro on of the critical-car

ace, and verify the moment of use, statuses ™gnment (VIPc)

om FFFom FFFogy frogy fr

ducts FFF t of use,

e-of-the-art,

Eli ihighEliminahi h va

Increase

high-va

tlue critical productsoducts

ctes carrying cosl i i l

ts ofd

es visibility of pro oduct

lue critical pr

Monit,

ors remotely priquantityquantity l, loca loca i dtion andtion and

temperature

r d

oduct d

iseprer©2014 FFF Ent

(800) 84 [email protected], Is

43-7477 x1142 | [email protected]

[email protected]

s to us as tomer

s a DISTRIBUTORs see us as MUCH

R.H M

MORE.

r

v oomers prcust

, FFF g escesourr

eams of o our tt

ABAFFORDFROM

.tstienor their pae fo vide the best car

o help tDISTRIBUTIONONDBEY goes olio of industtfo essionals and porofe pr

,YABILITAILVAAVANDYTSAFE, YBILIT

p our

y tr

h e mwhich w

eing HlpeH

pxE

b h e all our actions. uras me

is the b arethcare Cale

IDFFFehtecneirep

l h onsider e c We

y enchmark b

!ECNEREFFI

this no

.ya wonly, but the yat the FFF wt jus o ww

cerprises.ent.FFFww.ncerprises, Int14 FFF E20©

77477443-) 8800om | (c

(800) 843-7477 www.FFFenterprises.comFL215 0414

More than words, it is our commitment to a secure pharmaceutical supply chain.

neeed f lu vvacaccine? · 2014. 4. 10. · j7195 j7195 j7195 j7195 j7194 j7194 j3590 te *all codes...

Documents